With the approval of Ocrevus (ocrelizumab) for both primary progressive and relapsing multiple sclerosis (MS), interest in the medication is peaking. To help readers of Multiple Sclerosis News Today better understand this new medication and how it works, as well as issues dealing with access, use, and potential side effects, here is a summary of the most relevant information now available about Ocrevus.
Comments and concerns expressed by many readers on our different platforms were taken into consideration in writing this article.
Ocrevus is a prescription medication, so people considering the treatment should discuss with their physicians whether it may be suitable for them.
Genentech — Ocrevus’s developer — is working to make sure that patients receive adequate information about the therapy. The company has set up a website — http://www.ocrevus.com — with detailed information. Patients can also call 1-844-627-3887 (Ocrevus Connects, Monday to Friday, from 9 am to 8 pm ET) with questions concerning this therapy.
Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.